News/Events


news Coventry, R.I., October 1, 2012
 

Rhodes Pharmaceuticals L.P. Announces the Launch of Hydromorphone Hydrochloride Oral Solution, USP
Authorized Generic of Dilaudid® (hydromorphone hydrochloride) Oral Liquid

Rhodes Pharmaceuticals L.P. announces the expansion of its generic product portfolio with the addition of Hydromorphone Hydrochloride Oral Solution, USP. This is the company’s fifth product and it is the authorized generic of Dilaudid® Oral Liquid. This product is available in bottles of 1 pint (473 mL), 5 mg/5 mL.

"This is a welcomed expansion to our hydromorphone hydrochloride product line," said Robert Thebeau, Vice President of Sales and Marketing for Rhodes Pharmaceuticals L.P. "Our continued growth is attributed to our solid teamwork and dedication to providing exceptional customer service. As we continue to grow, we look forward to introducing more products to the market."

About Rhodes Pharmaceuticals L.P.

Rhodes Pharmaceuticals L.P. is a specialty pharmaceutical company based in Coventry, Rhode Island focused on the niche category. The company’s vision for success is based on a sustainable business platform supported by a critical mass of products and dosage forms, competitive costs and robust pipeline. For more information about Rhodes Pharmaceuticals L.P. visit www.rhodespharma.com.

For more complete information about the use of Hydromorphone Hydrochloride Oral Solution, USP, please see the FDA-approved Prescribing Information and Medication Guide posted on the FDA website http://www.accessdata.fda.gov/scripts/cder/drugsatfda/


news Coventry, R.I., March 1, 2012
 

Rhodes Pharmaceuticals L.P. Announces the Launch of Theophyilline (Andhydrous) Extended-Release
Company’s Fourth Generic Product

Rhodes Pharmaceuticals L.P. announced today the launch of Theophyilline (Andhydrous) Extended-Release Tablets. This product is available in strengths of 400 mg and 600 mg in bottles of 100 tablets.

"We are excited to introduce our product into the marketplace," said Robert Thebeau, Vice President of Sales and Marketing for Rhodes Pharmaceuticals L.P. "Our management team has extensive experience in the pharmaceutical industry and we look forward to expanding our product line."

About Rhodes Pharmaceuticals L.P.

Rhodes Pharmaceuticals L.P. is a specialty pharmaceutical company based in Coventry, Rhode Island focused on the niche category. The company’s vision for success is based on a sustainable business platform supported by a critical mass of products and dosage forms, competitive costs and robust pipeline. For more information about Rhodes Pharmaceuticals L.P. visit www.rhodespharma.com.

For more complete information about the use of Tramadol Hydrochloride Extended-Release Tablets, please see the FDA-approved Prescribing Information and Medication Guide posted on the FDA website http://www.accessdata.fda.gov/scripts/cder/drugsatfda/


news Coventry, R.I., February 1, 2011
 

Rhodes Pharmaceuticals L.P. Announces the Launch of Morphine Sulfate Extended-Release Tablets
Company’s Second Generic Product

Rhodes Pharmaceuticals L.P. announced today the launch of Morphine Sulfate Extended-Release Tablets.  This product is available in strengths of 15mg, 30mg, 60mg, 100mg, and 200mg each in bottles of 100 tablets.

“We are excited to introduce our product into the marketplace,” said Robert Thebeau, Vice President of Sales and Marketing for Rhodes Pharmaceuticals L.P.  “Our management team has extensive experience in the pharmaceutical industry and we look forward to expanding our product line.”

About Rhodes Pharmaceuticals L.P.

Rhodes Pharmaceuticals L.P. is a specialty pharmaceutical company based in Coventry, Rhode Island focused on the niche category.  The company’s vision for success is based on a sustainable business platform supported by a critical mass of products and dosage forms, competitive costs and robust pipeline.  For more information about Rhodes Pharmaceuticals L.P. visit www.rhodespharma.com.

For more complete information about the use of Morphine Sulfate Extended-Release, please see the FDA-approved Prescribing Information and Medication Guide posted on the FDA website http://www.accessdata.fda.gov/scripts/cder/drugsatfda/

The professional labeling for Morphine Sulfate Extended-Release contains the following Black Boxed warning:

WARNING:
Morphine Sulfate Extended-Release Tablets contain morphine sulfate, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics.

Morphine can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing Morphine Sulfate Extended-Release Tablets in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.

Morphine Sulfate Extended-Release Tablets is an extended-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

Morphine Sulfate Extended-Release Tablets is NOT intended for use as a prn analgesic.

Morphine Sulfate Extended-Release 100 and 200 mg Tablets ARE FOR USE IN OPIOID-TOLERANT PATIENTS ONLY. These tablet strengths may cause fatal respiratory depression when administered to patients not previously exposed to opioids.

MORPHINE SULFATE EXTENDED-RELEASE TABLETS ARE TO BE SWALLOWED WHOLE AND ARE NOT TO BE BROKEN, CHEWED, DISSOLVED, OR CRUSHED. TAKING BROKEN, CHEWED, DISSOLVED, OR CRUSHED MORPHINE SULFATE EXTENDED-RELEASE TABLETS LEADS TO RAPID RELEASE AND ABSORPTION OF A POTENTIALLY FATAL DOSE OF MORPHINE.



News Release Coventry, RI-December 8, 2009
 

Rhodes Pharmaceuticals L.P. announces the launch of Hydromorphone Hydrochloride Tablets, USP which is the authorized generic of Dilaudid® (hydromorphone hydrochloride). Hydromorphone Hydrochloride Tablets are now available in 2mg bottles of 100 tablets, 4mg bottles of 100 and 500 tablets, and 8mg bottles of 100 tablets.

Rhodes Pharmaceuticals L.P.is a specialty pharmaceutical company based in Coventry, RI focused on the niche category. Our vision for success is based on a sustainable business platform supported by a critical mass of products and dosage forms, competitive costs and robust pipeline.  For more information about Rhodes Pharmaceuticals L.P. visit www.rhodespharma.com

News Archives